Namenda’s success is a reflection of an unmet need in patients with moderate to severe Alzheimer’s disease in the United States. In Europe, memantine (Axura(R)) is established since May 2002 in the same indication.
Namenda’s success is a reflection of an unmet need in patients with moderate to severe Alzheimer’s disease in the United States. In Europe, memantine (Axura(R)) is established since May 2002 in the same indication.